Skip to main content
SNDX $8.72 -4.49%
SNDX logo
SNDX · Syndax Pharmaceuticals Inc
Track SNDX — free
$8.72 -0.41 (-4.49%) At close · Nov 20 Play latest call Q2 2026 earnings call transcript
Market Cap
$778.67M
Shares
89.30M
Volume · Nov 20 2.18M Avg daily vol (3M) 2.61M
All webcasts

Earnings call · FY2026 Q3

Syndax Pharmaceuticals Inc (SNDX) Q3 2026 Earnings Call

Concluded Nov 2, 2026
Nov 2, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $83.30M +81.6% YoY
Diluted EPS -$0.55
Net income -$49.43M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 2, 2026
Syndax Pharmaceuticals appointed Aaron A. Ondrey CFO effective November 9, 2026, succeeding retiring Keith A. Goldan. Ondrey receives a $543,000 annual salary, 45% target bonus and option for 270,000 shares.
10-Q report · filed Nov 2, 2026
Syndax reported third-quarter Revuforj net revenue of $60.7 million, up 90%, and Niktimvo net revenue of $67.4 million, up 47%. MAXPIRe missed its primary endpoint in IPF, and Syndax does not plan to move forward with further axatilimab development there.

The audio replay and transcript follow the call.

Forward guidance

4 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 2, 2026.

Metric Guided
Total research and development plus selling, general and adminis Maintained
full year of 2026
$400M
Peak annual net revenue
peak annual
at least $2B
Expected stock option expense
2026
$50M
Estimated non-cash stock compensation expense
full year of 2026
$50M

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Product$60.74M +89.8% YoY
Collaboration Revenue$22.55M +62.7% YoY
Full-screen source Call document